Terbutaline-induced desensitization of human lymphocyte beta 2-adrenoceptors. Accelerated restoration of beta-adrenoceptor responsiveness by prednisone and ketotifen

O E Brodde, M Brinkmann, R Schemuth, N O'Hara, A Daul, O E Brodde, M Brinkmann, R Schemuth, N O'Hara, A Daul

Abstract

We investigated, in 36 healthy volunteers, the effects of prednisone and ketotifen on recovery of lymphocyte beta 2-adrenoceptor density (determined by (-)-125iodocyanopindolol binding) and responsiveness (assessed by lymphocyte cyclic AMP [cAMP] responses to 10 microM (-)-isoprenaline) after desensitization by the beta 2-agonist terbutaline. Terbutaline (3 X 5 mg/d) decreased lymphocyte beta 2-adrenoceptor density by approximately 40-50%; concomitantly, lymphocyte cAMP responses to 10 microM (-)-isoprenaline were significantly reduced. After withdrawal of terbutaline beta 2-adrenoceptor, density and responsiveness gradually increased, reaching predrug levels after 4 d. Prednisone (1 X 100 mg orally) accelerated beta 2-adrenoceptor recovery; only 8-10 h after administration of the steroid beta 2-adrenoceptor density and cAMP responses to (-)-isoprenaline had reached values not significantly different from pretreatment levels. Similar effects were obtained with ketotifen (2 mg; thereafter 2 X 1 mg/d for 4 d): 24 h after application of the drug beta 2-adrenoceptor density and cAMP responses to (-)-isoprenaline had reached pretreatment levels. Furthermore, ketotifen simultaneously applied with terbutaline completely prevented terbutaline-induced decrease in lymphocyte beta 2-adrenoceptor density and responsiveness. Prednisone (1 X 100 mg orally) or ketotifen (2 mg; thereafter 2 X 1 mg/d for 2 d) had no significant influence on lymphocyte beta 2-adrenoceptor density in healthy volunteers not pretreated with terbutaline, but shifted the ratio high-to-low affinity state of the lymphocyte beta 2-adrenoceptor toward high affinity state. We conclude that glucocorticoids as well as ketotifen can accelerate recovery of density and responsiveness of lymphocyte beta 2-adrenoceptors desensitized by long-term treatment with beta 2-agonists. Such an effect may have clinical implications for preventing tachyphylaxis of asthmatic patients against therapy with beta 2-agonists.

References

    1. J Pharmacol Exp Ther. 1966 Nov;154(2):224-38
    1. J Recept Res. 1984;4(1-6):37-50
    1. Proc Natl Acad Sci U S A. 1970 Sep;67(1):305-12
    1. Br J Pharmacol. 1971 Oct;43(2):389-402
    1. J Biol Chem. 1972 Jun 10;247(11):3579-88
    1. Naunyn Schmiedebergs Arch Pharmacol. 1972;273(1):134-53
    1. Naunyn Schmiedebergs Arch Pharmacol. 1972;274(3):287-98
    1. Lancet. 1975 Dec 27;2(7948):1269-71
    1. J Clin Invest. 1976 Dec;58(6):1307-16
    1. J Allergy Clin Immunol. 1977 May;59(5):383-90
    1. Lancet. 1977 Aug 20;2(8034):375-7
    1. Am Rev Respir Dis. 1977 Nov;116(5):871-8
    1. J Cyclic Nucleotide Res. 1977 Dec;3(6):439-46
    1. Br J Clin Pharmacol. 1978 Mar;5(3):199-206
    1. N Engl J Med. 1978 Oct 26;299(17):933-6
    1. Res Commun Chem Pathol Pharmacol. 1978 Nov;22(2):233-42
    1. Proc Natl Acad Sci U S A. 1979 Jun;76(6):3024-8
    1. J Allergy Clin Immunol. 1980 Feb;65(2):105-9
    1. J Clin Invest. 1980 Mar;65(3):577-85
    1. Schweiz Med Wochenschr. 1980 Feb 9;110(6):197-203
    1. J Biol Chem. 1980 Aug 10;255(15):7410-9
    1. J Clin Endocrinol Metab. 1980 Sep;51(3):599-605
    1. Br J Clin Pharmacol. 1980 Nov;10(5):417-23
    1. Clin Allergy. 1980 Sep;10(5):519-25
    1. J Clin Endocrinol Metab. 1981 Oct;53(4):703-8
    1. Life Sci. 1981 Nov 23;29(21):2189-98
    1. Naunyn Schmiedebergs Arch Pharmacol. 1981;317(4):277-85
    1. Am Rev Respir Dis. 1982 Feb;125(2):185-93
    1. J Allergy Clin Immunol. 1982 May;69(5):410-7
    1. N Engl J Med. 1982 Jul 1;307(1):18-29
    1. Poumon Coeur. 1982 Mar-Apr;38(2):125-9
    1. Fed Proc. 1982 Aug;41(10):2664-70
    1. Clin Pharmacol Ther. 1982 Nov;32(5):566-71
    1. J Allergy Clin Immunol. 1982 Dec;70(6):417-22
    1. Life Sci. 1982 Oct 11;31(15):1567-73
    1. J Pharmacol Exp Ther. 1983 Jan;224(1):1-6
    1. J Biol Chem. 1983 Mar 10;258(5):3032-8
    1. J Clin Invest. 1983 Mar;71(3):565-71
    1. Eur J Pharmacol. 1983 Jan 21;86(3-4):321-8
    1. Eur J Clin Invest. 1983 Aug;13(4):339-46
    1. J Allergy Clin Immunol. 1983 Nov;72(5 Pt 1):495-503
    1. Pharmacol Rev. 1983 Mar;35(1):5-32
    1. Physiol Rev. 1984 Apr;64(2):661-743
    1. Annu Rev Physiol. 1984;46:119-30
    1. Naunyn Schmiedebergs Arch Pharmacol. 1984 Feb;325(2):190-2
    1. Am Rev Respir Dis. 1984 Dec;130(6):1023-6
    1. Br J Pharmacol. 1969 Jul;36(3):582-93

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe